Korro Bio, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Korro Bio, Inc. (KRRO) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 1.80 million shares for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2025-11-12
- Korro Bio, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 1.71M shares, a 33.58% increase year-over-year.
- Korro Bio, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 1.28M shares, a 86.13% decline year-over-year.
- Korro Bio, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 9.24M shares, a 5.31% increase year-over-year.
- Korro Bio, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2022-03-31 was 8.78M shares, a 13.89% increase year-over-year.
- Korro Bio, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2021 was 7.46M shares, a 9.33% increase from fiscal 2020.
- Korro Bio, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2020 was 6.82M shares, a 65.12% decline from fiscal 2019.
- Korro Bio, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2019 was 19.55M shares, a 5.10% increase from fiscal 2018.
- Korro Bio, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2018 was 18.61M shares, a 70.60% increase from fiscal 2017.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|---|
| 2025-09-30 | 1.80M shares 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | 1.79M shares 10-Q · filed 2025-08-12 | ||||
| 2025-03-31 | 1.71M shares 10-Q · filed 2025-05-07 | ||||
| 2024-09-30 | 1.29M shares 10-Q · filed 2025-11-12 | ||||
| 2024-06-30 | 1.31M shares 10-Q · filed 2025-08-12 | ||||
| 2024-03-31 | 1.28M shares 10-Q · filed 2025-05-07 | ||||
| 2023-09-30 | 6.59M shares 10-Q · filed 2023-11-02 | ||||
| 2023-06-30 | 7.84M shares 10-Q · filed 2023-08-10 | ||||
| 2023-03-31 | 9.24M shares 10-Q · filed 2023-05-12 | ||||
| 2022-09-30 | 8.86M shares 10-Q · filed 2023-11-02 | ||||
| 2022-06-30 | 8.37M shares 10-Q · filed 2023-08-10 | ||||
| 2022-03-31 | 8.78M shares 10-Q · filed 2023-05-12 | ||||
| 2021-12-31 | 7.46M shares 10-K · filed 2022-03-15 | ||||
| 2021-09-30 | 7.98M shares 10-Q · filed 2021-11-15 | 7.98M shares 10-Q · filed 2021-11-15 | |||
| 2021-06-30 | 8.39M shares 10-Q · filed 2021-08-12 | 8.39M shares 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | 7.71M shares 10-Q · filed 2022-05-04 | ||||
| 2020-12-31 | 6.82M shares 10-K · filed 2022-03-15 | ||||
| 2020-09-30 | 6.76M shares 10-Q · filed 2021-11-15 | 6.76M shares 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | 6.81M shares 10-Q · filed 2021-08-12 | 6.81M shares 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | 6.91M shares 10-Q · filed 2021-05-13 | ||||
| 2019-12-31 | 19.55M shares 10-K · filed 2021-03-29 | ||||
| 2019-09-30 | 26.99M shares 10-Q · filed 2020-11-16 | 29.99M shares 10-Q · filed 2019-11-18 | 26.99M shares 10-Q · filed 2020-11-16 | ||
| 2019-06-30 | 20.79M shares 10-Q · filed 2020-08-12 | 20.79M shares 10-Q · filed 2020-08-12 | |||
| 2019-03-31 | 18.38M shares 10-Q · filed 2020-05-14 | ||||
| 2018-12-31 | 18.61M shares 10-K · filed 2020-03-26 | ||||
| 2018-09-30 | 11.74M shares 10-Q · filed 2019-11-18 | 11.74M shares 10-Q · filed 2019-11-18 | |||
| 2017-12-31 | 10.91M shares 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |